Data / Drug companies / Monoamine Oxidase Inhibitor
Monoamine Oxidase Inhibitor drugs: 8 drugs from 37 companies in the FDA NDC directory
Monoamine Oxidase Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 60 products in this class from 37 companies, covering 8 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on October 20, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 37Companies
- 60Products
- 8Drugs by generic name
Drugs in the Monoamine Oxidase Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Selegiline hydrochloride | 14 | 12 |
| Rasagiline | 21 | 11 |
| Rasagiline mesylate | 12 | 6 |
| Phenelzine sulfate | 3 | 3 |
| Tranylcypromine | 3 | 3 |
| Tranylcypromine sulfate | 3 | 3 |
| Selegiline | 3 | 1 |
| Isocarboxazid | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Chartwell RX, LLC | 3 | tablet | Generic drugs (ANDA) | July 27, 2018 |
| Remedyrepack Inc. | 3 | tablet | Generic drugs (ANDA) | August 25, 2026 |
| Viatris Specialty LLC | 3 | patch | New drug applications (NDA) | February 27, 2006 |
| Alvogen Inc. | 2 | tablet | Generic drugs (ANDA) | March 1, 2019 |
| Ani Pharmaceuticals, Inc. | 2 | tablet; capsule | Generic drugs (ANDA) | June 6, 2021 |
| Apotex Corp. | 2 | capsule; tablet | Generic drugs (ANDA) | July 15, 1997 |
| Ascend Laboratories, LLC | 2 | tablet | Generic drugs (ANDA) | October 30, 2017 |
| Aurobindo Pharma Limited | 2 | tablet | Generic drugs (ANDA) | October 20, 2026 |
| Bryant Ranch Prepack | 2 | capsule | Generic drugs (ANDA) | April 1, 2021 |
| Carnegie Pharmaceuticals LLC | 2 | tablet | Generic drugs (ANDA) | January 15, 2026 |
| Florida Pharmaceutical Products, LLC | 2 | tablet | Generic drugs (ANDA) | April 14, 2026 |
| Golden State Medical Supply, Inc. | 2 | tablet | Generic drugs (ANDA) | November 18, 2021 |
| Macleods Pharmaceuticals Limited | 2 | tablet | Generic drugs (ANDA) | June 29, 2024 |
| Micro Labs Limited | 2 | tablet | Generic drugs (ANDA) | April 3, 2019 |
| NorthStar Rx LLC | 2 | tablet | Generic drugs (ANDA) | April 17, 2018 |
| Rising Pharma Holdings, Inc. | 2 | tablet | Generic drugs (ANDA) | July 21, 2025 |
| SKG Pharma Inc. | 2 | tablet | Generic drugs (ANDA) | April 4, 2025 |
| Teva Neuroscience, Inc. | 2 | tablet | New drug applications (NDA) | July 10, 2006 |
| Teva Pharmaceuticals USA, Inc. | 2 | tablet | Authorized generics (NDA) | January 3, 2017 |
| Torrent Pharmaceuticals Limited | 2 | tablet | Generic drugs (ANDA) | November 15, 2025 |
| A-S Medication Solutions | 1 | tablet | Generic drugs (ANDA) | July 6, 1997 |
| A2A Integrated Pharmaceuticals | 1 | tablet | Generic drugs (ANDA) | March 15, 2024 |
| Actavis Pharma, Inc. | 1 | tablet, film coated | Authorized generics (NDA) | February 5, 2016 |
| Advanz Pharma (US) Corp. | 1 | tablet, film coated | New drug applications (NDA) | January 14, 2013 |
| Bausch Health US LLC | 1 | tablet, orally disintegrating | New drug applications (NDA) | June 14, 2006 |
| Bryant Ranch Prepack | 1 | tablet | Generic drugs (ANDA) | April 3, 2019 |
| Golden State Medical Supply, Inc. | 1 | tablet | Generic drugs (ANDA) | June 6, 1997 |
| I3 Pharmaceuticals, LLC | 1 | tablet | Generic drugs (ANDA) | December 15, 2021 |
| Lifsa Drugs LLC | 1 | tablet | New drug applications (NDA) | July 1, 1959 |
| Lupin Pharmaceuticals,Inc. | 1 | tablet | Generic drugs (ANDA) | December 14, 2010 |
| Marlex Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | May 1, 2021 |
| Mylan Pharmaceuticals Inc. | 1 | tablet, film coated | Authorized generics (NDA) | March 23, 2011 |
| Parke-Davis Div of Pfizer Inc | 1 | tablet, film coated | New drug applications (NDA) | June 9, 1961 |
| Proficient Rx LP | 1 | capsule | Generic drugs (ANDA) | April 2, 2019 |
| Rising Pharma Holdings, Inc. | 1 | capsule | Generic drugs (ANDA) | April 2, 2019 |
| Solco Healthcare US, LLC | 1 | tablet | Generic drugs (ANDA) | December 10, 2022 |
| Strides Pharma Science Limited | 1 | tablet, film coated | Generic drugs (ANDA) | April 11, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 44 | 73.3% |
| Capsule | 7 | 11.7% |
| Tablet, film coated | 5 | 8.3% |
| Patch | 3 | 5% |
| Tablet, orally disintegrating | 1 | 1.7% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.